Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D et al..
2007.
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 369(9579):2097-105.
Stavarache MA, Petersen N, Jurgens EM, Milstein ER, Rosenfeld ZB, Ballon DJ, Kaplitt MG.
2018.
Safe and stable noninvasive focal gene delivery to the mammalian brain following focused ultrasound. J Neurosurg. 130(3):989-998.
Fishman PS, W Elias J, Ghanouni P, Gwinn R, Lipsman N, Schwartz M, Chang JW, Taira T, Krishna V, Rezai A et al..
2018.
Neurological adverse event profile of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor.. Mov Disord. 33(5):843-847.
Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A et al..
2017.
Long-term follow-up of a randomized AAV2- gene therapy trial for Parkinson's disease.. JCI Insight. 2(7):e90133.
Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C, Pey E, Zhao L, Arbona RJRicart, Monette S et al..
2018.
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.. Hum Gene Ther Clin Dev. 29(1):24-47.